# InspireMD, Inc. > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/fi/companies/InspireMD, Inc.). ## Overview InspireMD, Inc. develops and commercializes carotid stent systems used to treat carotid artery disease and help prevent stroke. The company is transitioning from a development-focused medical device business to a direct commercial model, with CGuard Prime as its lead product and a growing U.S. launch effort supported by manufacturing and distribution partners. ## Products & services • CGuard Prime carotid stent system • Carotid artery disease treatment devices • Direct sales, training and clinical support • Distribution and commercialization services • Contract-manufactured finished goods supply - **Carotid stent systems** (85%) — Implantable stent products used in carotid artery interventions to reduce stroke risk. - **Commercialization and support services** (10%) — Sales, training, market access and medical affairs support for product adoption. - **Manufacturing and supply chain services** (5%) — Third-party manufacturing and production transfer activities supporting product supply. - CGuard Prime carotid stent system - Carotid artery disease treatment devices - Direct sales, training and clinical support - Distribution and commercialization services - Contract-manufactured finished goods supply ## Customers InspireMD sells primarily to hospitals, interventional physicians and vascular specialists that perform carotid procedures. Demand is driven by clinical adoption, physician access, reimbursement coverage and the ability to demonstrate product benefits versus alternative treatment options. - **Hospitals and surgical centers** (primary) — Buy carotid stent systems for use in inpatient and outpatient vascular procedures. - **Interventional physicians and vascular specialists** (primary) — Use and recommend the product based on clinical performance and ease of adoption. - **Third-party payors** (secondary) — Influence utilization through coverage and reimbursement decisions for carotid procedures. - **Commercial partners and distributors** (secondary) — May support U.S. launch, co-promotion and market access if direct commercialization is insufficient. - Hospitals purchasing devices for carotid intervention procedures - Interventional physicians and vascular specialists using the stent - Physicians and key opinion leaders influencing adoption - Third-party payors affecting reimbursement and utilization - Potential U.S. commercialization partners for market expansion ## Geography The company is headquartered in Miami, Florida, but its operational footprint remains tied to Israel and the U.S. commercial build-out. Management has highlighted North Carolina contract manufacturing for CGuard Prime and exposure to Israel-related geopolitical and trade risks, which can affect supply continuity, costs and lead times. - Global headquarters in Miami, Florida - U.S. commercialization build-out for CGuard Prime - Manufacturing transfer to Aptyx in North Carolina - Israeli operating exposure creates geopolitical risk - U.S.-Israel trade policy can affect cost of goods and logistics ## Strategy The core strategy is to establish CGuard Prime in the U.S. market through a direct sales organization, distribution capability and clinical support infrastructure. At the same time, the company is diversifying manufacturing through a third-party partner to scale production and reduce execution risk as commercialization expands. - **U.S. commercialization of CGuard Prime** (short-term) — The U.S. market is the main growth opportunity and requires physician adoption, reimbursement and sales execution. - **Manufacturing scale-up and supply continuity** (short-term) — Commercial success depends on reliable production and the ability to meet demand without disrupting quality or supply. - **Partnership flexibility** (medium-term) — If direct commercialization underperforms, collaboration can extend reach but may dilute economics. - Launch CGuard Prime in the United States - Build direct sales, training and market access capabilities - Expand physician adoption through clinical education - Transfer manufacturing to support higher production volumes - Use partnerships if direct commercialization is not efficient ## Risks The business is highly execution-dependent because revenue growth relies on successfully launching CGuard Prime and building a sales force, distribution network and manufacturing base. It also faces meaningful geopolitical and trade exposure from Israel-related operations, plus the usual medical device risks around physician adoption, reimbursement, product liability and regulatory scrutiny. - **U.S. commercialization execution risk** [high] — The company is investing heavily in direct sales, training and distribution, but adoption may lag expectations. - **Manufacturing and supply chain dependence** [high] — Production is being transferred to a third-party manufacturer, creating quality, timing and capacity risk. - **Geopolitical exposure to Israel** [high] — Conflict, sanctions or disruption in Israel could affect operations, logistics and profitability. - **Trade policy and tariff risk** [medium] — Tariffs on medical devices or Israel-linked imports could increase cost of goods sold and reduce pricing flexibility. - **Market acceptance and reimbursement risk** [high] — Physician adoption and third-party payor coverage determine procedure volumes and commercial success. - U.S. launch failure would delay revenue and waste commercialization spend - Sales force build-out is costly and hard to execute quickly - Dependence on third-party manufacturing can disrupt supply and margins - Israel geopolitical conflict could affect operations and profitability - Tariffs or customs changes may raise COGS and lengthen lead times - Physician adoption and reimbursement uncertainty can limit market uptake ## Accounting Investors should watch how the company capitalizes or expenses commercialization and manufacturing ramp costs, since launch spending can be significant before revenue scales. Revenue recognition is likely tied to device shipments and distributor arrangements, while inventory, warranty, and potential product liability or restructuring-related estimates can move reported results materially. - **Revenue recognition for device sales and partner arrangements** — Can shift revenue between quarters and affect comparability. - **Inventory and manufacturing transfer accounting** — Can affect gross margin and working capital. - **Commercialization expense recognition** — Can suppress near-term operating results. - **Contingencies and product liability provisions** — Can create earnings volatility if reserves change. - Commercial launch costs may be expensed before revenue scales - Revenue timing may depend on product shipment and distributor terms - Inventory and manufacturing transfer costs can affect gross margin - Warranty and product liability estimates may require judgment - Potential impairment risk if commercialization assets underperform --- *Last updated: 2026-04-28T20:17:40.124045+00:00*